What are Cardiac glycoside drugs?

Cardiac glycoside drugs are pharmacologic agents that share a common mechanism (typically targeting Na+/K+-ATPase). 0 are currently marketed, with 3 more in clinical development.

Cardiac glycoside

0 marketed 2 in Phase 3 1 in Phase 1

This page covers all Cardiac glycoside drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Na+/K+-ATPase, Sodium-potassium ATPase.

Targets

Na+/K+-ATPase · Sodium-potassium ATPase

Phase 3 pipeline (2)

Intra-amniotic injection of DIGOXIN · Meir Medical Center · Cardiology
Intra-amniotic digoxin administration aims to treat fetal cardiac arrhythmias by crossing fetal membranes and exerting direct cardiac glycoside effects on fetal myocardium.
Digoxin (0.25mg) · Advenchen Laboratories, LLC · Cardiovascular
Digoxin inhibits the Na+/K+-ATPase pump, increasing intracellular calcium and enhancing cardiac contractility while slowing atrioventricular node conduction.

Phase 1 pipeline (1)

AB-106, digoxin · Nuvation Bio Inc. · Cardiovascular
Digoxin inhibits the sodium-potassium ATPase pump.